{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"5"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"4"},{"groupId":"OG022","value":"10"},{"groupId":"OG023","value":"5"},{"groupId":"OG024","value":"4"},{"groupId":"OG025","value":"4"},{"groupId":"OG026","value":"13"},{"groupId":"OG027","value":"10"},{"groupId":"OG028","value":"13"}],"units":"Participants"}],"description":"A DLT was assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v 4.0, and considered by the investigators to be related to AMG 176. A DLT was defined as a grade 3 or higher non-hematological or a grade 4 hematologic adverse event (AE) that occurred during the DLT observation period.\n\nCTCAE is graded from grade 1 to 5, with higher grades indicating a worse outcome, and included; grade 1 = mild, grade 2= moderate, grade 3 = severe, grade 4 = life-threatening, and grade 5 = death.","groups":[{"description":"Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG000","title":"Part 1A Cohort 1 (MM): AMG 176 Dose A BIW"},{"description":"Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG001","title":"Part 1A Cohort 2 (MM): AMG 176 Dose B BIW"},{"description":"Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG002","title":"Part 1A Cohort 3 (MM): AMG 176 Dose C BIW"},{"description":"Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG003","title":"Part 1A Cohort 4 (MM): AMG 176 Dose D BIW"},{"description":"Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG004","title":"Part 1A Cohort 5 (MM): AMG 176 Dose E BIW"},{"description":"Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG005","title":"Part 1A Cohort 6 (MM): AMG 176 Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG006","title":"Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG007","title":"Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG008","title":"Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG009","title":"Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG010","title":"Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG011","title":"Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG012","title":"Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG013","title":"Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW"},{"description":"Participants with AML received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG014","title":"Part 3A Cohort 1 (AML): AMG 176 Dose D BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG015","title":"Part 3A Cohort 2 (AML): AMG 176 Dose E BIW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG016","title":"Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW"},{"description":"Japanese participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG017","title":"Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG018","title":"Part 3B Cohort 1 (AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG019","title":"Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG020","title":"Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW"},{"description":"Japanese participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG021","title":"Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 200 mg itraconazole QD for 7 days in week 1.","id":"OG022","title":"Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG023","title":"Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG024","title":"Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG025","title":"Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG026","title":"Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG027","title":"Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for for 7 days in week 1.","id":"OG028","title":"Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT-evaluable analysis set included participants if they experienced a DLT during the DLT evaluation period or if they received at least 75% of the planned doses of AMG 176 (and 100% of the planned doses of azacitidine in Part 4) and completed the DLT evaluation period.","reportingStatus":"POSTED","timeFrame":"Days 1 to 28 of cycle 1 (4 weeks)","title":"Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)","type":"PRIMARY","unitOfMeasure":"Participants"}